Fax: (716) 845-2343
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia†
Article first published online: 31 MAR 2011
Copyright © 2011 American Cancer Society
Volume 117, Issue 21, pages 4831–4868, 1 November 2011
How to Cite
Wetzler, M., Andrews, C., Ford, L. A., Tighe, S., Barcos, M., Sait, S. N. J., Block, A. W., Nowak, N. J., Baer, M. R., Wang, E. S. and Baumann, H. (2011), Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer, 117: 4831–4868. doi: 10.1002/cncr.26097
The first author was the principal investigator of this protocol, oversaw patient accrual, contributed to the care of the patients, followed data collection, reviewed the data, and wrote the article The second author performed the statistical analyses. The third author constructed the database. The fourth author served as the research coordinator for this protocol. The fifth author reviewed the pathology specimens. The sixth and seventh authors reviewed all karyotype analyses. The eighth author oversaw the single nucleotide polymorphism analysis. The ninth author was the principal investigator on the high-dose cytarabine and idarubicin trials, served as a coinvestigator on this protocol, and contributed to the care of the patients. The 10th author contributed to the care of the patients. The 11th author was a senior coinvestigator on this protocol. All authors reviewed and approved the final article.
- Issue published online: 19 OCT 2011
- Article first published online: 31 MAR 2011
- Manuscript Accepted: 10 FEB 2011
- Manuscript Revised: 1 FEB 2011
- Manuscript Received: 9 NOV 2010
- 7High-dose cytarabine and idarubicin induction produces a high complete remission (CR) rate in previously untreated de novo acute myeloid leukemia (AML) patients (pts) <60 years old [abstract]. Blood. 2000; 96: 322a., , , et al.
- 11Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336., , , et al.